First patient in on ELC-301 has completed and interim results of three patients is due Q1-2025, where safety and effect will already be measured, so according to CEO we might already see the anti-tumor effect at lowest dosage, which will be a high share price driver, and a 5 x share price rally H1 2025 would be possible given the already low valuation of the company.

Just a moment...

(www.redeye.se)

here is link in Swedish where CEO presents the company and the latest clinical trial.

Attention Required! | Cloudflare

(www.biostock.se)

Link in swedish to interview with CEO where he is very optimistic about the company.

https://discord.gg/SzwSQFE6SC link to community.